The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 21.00
Bid: 20.50
Ask: 21.50
Change: 0.00 (0.00%)
Spread: 1.00 (4.878%)
Open: 20.75
High: 21.00
Low: 19.75
Prev. Close: 21.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Angle soars on clinical tests; Likewise sales up

Thu, 04th Jan 2024 10:43

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Angle PLC, up 62% at 21.50 pence, 12-month range 9.07p-48.50p. Shares in the medical diagnostics firm soar after it unveils "breakthrough" clinical results from DNA molecular analysis of cancer patient blood samples that "provide a unique insight into the progression of each patient's cancer and how this may be treated". Angle says the results "highlight the potential for the Parsortix system to identify key variants [of] DNA mutations missed by other approaches to help guide treatment decisions." Chief Executive Officer Andrew Newland says: "Today's breakthrough is the critical next step post the [US Food & Drug Administration] clearance to show in a sample-to-answer format the potential clinical value of [next generation sequencing] molecular analysis on a repeat basis of living cancer cells harvested from patient blood samples. Angle is committed to delivering transformational benefits to cancer patients through a simple blood test. This is a major step in this process."

----------

Likewise Group PLC, up 15% at 23.00p, 12-month range 14.00p-28.00p. The domestic and commercial floor coverings distributor says 2023 gross sales revenue rose 14% to GBP140.2 million from a year earlier, while sales in Likewise Floors rose 29%. It says these increases are "particularly positive given the macro economic headwinds and subsequent challenging market conditions". Likewise says 2023 sales revenue is ahead of current market expectations and underlying profitability is expected to be in line with market expectations, reflecting the continued investment in the future of the business. Looking ahead, it is confident of achieving current market expectations for 2024, as it "continues to develop its position in the UK flooring market".

----------

AIM - LOSERS

----------

Landore Resources Ltd, down 13% at 2.70p, 12-month range 2.33p-18.37p. The Ontario, Canada-focused precious and base metal project explorer and developer raises GBP600,000 via a placing and subscription of 25.0 million new shares at a price of 2.4p each. The net proceeds of the fundraising will be used for general working capital purposes and to progress its strategy towards advancing its flagship BAM gold project at the Junior Lake property in northwestern Ontario. It says the new shares represent around 17% of its enlarged share capital. Landore also says Chief Executive Officer Claude Lemasson resigns with immediate effect, with Glenn Featherby assuming the role of interim CEO.

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
4 Jan 2024 12:09

LONDON MARKET MIDDAY: Retailers Next and JD Sports bookend FTSE 100

(Alliance News) - Stock prices in London were slightly higher at midday on Thursday, with the FTSE 100 looking set to snap the two-day losing streak it suffered at the start of the year.

Read more
4 Jan 2024 08:58

LONDON MARKET OPEN: Next leads buoyant FTSE 100 amid services PMIs

(Alliance News) - Stock prices in London opened up on Thursday, amid a slew of services PMI data, including for the UK, while reacting to the latest data from China.

Read more
4 Jan 2024 07:58

Angle receives 'breakthrough results' from DNA molecular analysis

(Sharecast News) - Liquid biopsy company Angle received "breakthrough results" from DNA molecular analysis of cancer patient blood samples on Thursday, sending its shares skywards as a result.

Read more
2 Jan 2024 09:04

Angle locks in $250,000 contract with Eisai

(Sharecast News) - Liquid biopsy company Angle has locked in a $250,000 contract with global pharmaceutical company Eisai to deliver circulating tumour cell analysis in a pilot study.

Read more
2 Jan 2024 08:51

IN BRIEF: Angle teams with Japan's Eisai in breast cancer drug trial

Angle PLC - Surrey, England-based medical diagnostics - Signs contract with Eisai Inc, part of Tokyo-based pharmaceutical firm Eisai Co Ltd. Under the agreement, the two will engage in a pilot study worth USD250,000 to Angle. Angle will provide circulating-tumour-cells analysis using its Portrait HER2 assay to assess the response of breast cancer patients to Eisai's BB-1701 antibody-drug conjugate. BB-1701 targets HER2, a protein that speeds up the growth of breast cancer cells. Success in the phase two pilot study will offer the possibility for multiple follow-up studies.

Read more
11 Dec 2023 20:44

TRADING UPDATES: Ondine Biomedical raises GBP2.9 million via placing

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
5 Dec 2023 11:50

IN BRIEF: Angle launches diagnostic kit at cancer symposium

Angle PLC - Surrey, England-based medical diagnostics company - Launches its Portrait Plus CTC staining kit at the San Antonio Breast Cancer Symposium, following "extensive" development, optimisation and validation of the kit. Explains that the kit is read-to-use, and designed for the dentification, characterisation and enumeration of epithelial and mesenchymal cancer cells. This includes those undergoing epithelial-to-mesenchymal transition.

Read more
9 Nov 2023 14:29

Angle says build up of revenue slower than hoped; launches test

(Alliance News) - Angle PLC on Thursday said it expects revenue in 2023 to more than double from 2022 as it announced the launch of a new test aimed to support cancer therapy studies.

Read more
25 Oct 2023 17:28

TRADING UPDATES: Franchise Brands trading in line; Tribe secures loan

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
3 Oct 2023 13:02

Angle hails study which shows Parsortix outperforming lab standard

(Alliance News) - Angle PLC on Tuesday touted the publication of a study by researchers at the University of Tubingen in Germany, which showed that its Parsortix system outperformed the current laboratory standard for disseminated tumour cell harvest.

Read more
14 Sep 2023 09:22

LONDON BROKER RATINGS: JPMorgan ups Rio Tinto; Redburn likes Carnival

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
7 Sep 2023 14:41

EARNINGS UPDATES: Sylvania beats production goal, Angle revenue surges

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on xxxday and not separately reported by Alliance News:

Read more
7 Sep 2023 11:20

AIM WINNERS & LOSERS: CVS plunges on CMA vet probe; Angle ascends

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
4 Sep 2023 14:21

Angle launches tumour cell assay to "unlock" customised cancer care

(Alliance News) - Angle PLC on Monday announced the launch of its new Portrait Flex circulating tumour cell assay, which it said will provide valuable trial data and help advance "personalised cancer care."

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.